Ran Zheng
Director/Board Member en CARIBOU BIOSCIENCES, INC. .
Fortuna: - $ al 31/03/2024
Perfil
Ran Zheng is currently the Chief Executive Officer & Director at Landmark Bio PBLLC and an Independent Director at Caribou Biosciences, Inc. Previously, she worked as the Vice President-Development Supply Chain at Amgen, Inc. and as the Chief Technical Officer at Orchard Therapeutics Plc.
She received a graduate degree from the University of Minnesota and an undergraduate degree from Beijing Forestry University.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 20/02/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Cargos activos de Ran Zheng
| Empresas | Cargo | Inicio |
|---|---|---|
| CARIBOU BIOSCIENCES, INC. | Director/Board Member | 24/09/2021 |
| Landmark Bio PBLLC | Chief Executive Officer | 01/03/2021 |
Antiguos cargos conocidos de Ran Zheng.
| Empresas | Cargo | Fin |
|---|---|---|
| ORCHARD THERAPEUTICS PLC | Chief Tech/Sci/R&D Officer | 01/02/2021 |
| AMGEN INC. | Corporate Officer/Principal | - |
Formación de Ran Zheng.
| University of Minnesota | Graduate Degree |
| Beijing Forestry University | Undergraduate Degree |
Experiencias
Funciones ocupadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| AMGEN INC. | Health Technology |
| CARIBOU BIOSCIENCES, INC. | Health Technology |
| Empresas privadas | 2 |
|---|---|
Orchard Therapeutics Plc
 Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
| Landmark Bio PBLLC |
- Bolsa de valores
- Insiders
- Ran Zheng
